SEARCH

SEARCH BY CITATION

References

  • 1
    Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med 1984; 76: 82741.
  • 2
    De The H, Chomienne C, Lanotte M, Degos L, Dejean A. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990; 347: 55861.
  • 3
    Groopman J, Ellman L. Acute promyelocytic leukemia. Am J Hematol 1979; 7: 395408.
  • 4
    Cordonnier C, Vernant JP, Brun B, Heilmann MG, Keuntz M, Bierling P, Farcet JP, Rodet M, Daedari N, Imbert M, Joquit H, Mannoni P, Reyea F, Dreyfus B, Rochant H. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 1825.
  • 5
    Sanz MA, Jarque I, Martin G. Acute promyelocytic leukemia therapy results and prognostic factors. Cancer 1988; 1: 713.
  • 6
    Cunningham I, Gee TS, Reich LM, Kempin SJ, Naval AN, Clarkson BD. Acute promyelocytic leukemia: treatment results during a decade at Memorial Hospital. Blood 1989; 73: 111622.
  • 7
    Rodeghiero F, Avvisati G, Castaman G, Barbui T, Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia: a GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 21127.
  • 8
    Fenaux P, Tertian G, Castaigne S, Tilly H, Leverger G, Guy H, Bordessoule D, Leblay R, Le Gall E, Colombat, Tchernia G, Bauters F, Marty M. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J Clin Oncol 1991; 9: 155661.
  • 9
    Bassan R, Battista R, Viero P, D'Emilio A, Buelli M, Montaldi A, Rambaldi A, Tremul L, Dini E, Barbui T. Short-term treatment for adult hypergranular and microgranular acute promyelocytic leukemia. Leukemia 1995; 9: 23843.
  • 10
    Tallman MS, Kwaan HC. Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 1992; 79: 54353.
  • 11
    Tallman MS, Hakimian D, Kwaan HC, Rickles FR. New insights into the pathogenesis of coagulation dysfunction in acute promyelocytic leukemia. Leuk Lymph 1993; 11: 2736.
  • 12
    Dombret H, Scrobohaci ML, Ghorra P, Zini JM, Daniel MT, Castaigne S, Degos L. Coagulation disorders associated with acute promyelocytic leukemia: corrective effect of all-trans retinoic acid treatment. Leukemia 1993; 7: 29.
  • 13
    Barbui T, Finazzi G, Falanga A. The impact of all-trans retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 1998; 91: 300933102.
  • 14
    Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, Gu LJ, Wang ZY. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 56772.
  • 15
    Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. All trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. i. Clinical results. Blood 1990; 76: 17049.
  • 16
    Warrell RP, Jr, Frankel SR, Miller WH, Jr, Scheinberg DA, Itri LM, Hittelman WN, Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS, Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). New Eng J Med 1991; 324: 138593.
  • 17
    Chen Z, Xue YQ, Zhang R, Tao RF, Xia XM, Li C, Wang W, Zu Wy Yao XZ, Ling BJ. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients. Blood 1991; 78: 14139.
  • 18
    Fenaux P, Castaigne S, Dombret H, Archimbaud E, Duarte M, Morel P, Lamy T, Tilly H, Guerci A, Maloisel F, Bordessoule D, Sadoun A, Tiberghein P, Fegueux N, Daniel MT, Chomienne C, Degos L. All-trans retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia. a pilot study on 26 cases. Blood 1992; 80: 217681.
  • 19
    Ohno R, Yoshida H, Fukutani H, Naoe T, Ohshima T, Kyo T, Endoh N, Fujimoto T, Kobayashi T, Kiraoka A, Mizoguchi H, Kodera Y, Suziki H, Hirano M, Akiyama H, Aoki N, Shindo H, Yokomaku S. The Leukemia Study Group of the Ministry of Health and Welfare. Multi-institutional study of all-trans retinoic acid as a differentiation therapy of refractory acute promyelocytic leukemia. Leukemia 1993; 7: 17227.
  • 20
    Fenaux P, Le Deley MC, Castaigne S, Archimbaud E, Chomienne C, Link H, Guerci A, Duarte M, Daniel MT, Bowen D, Huebner G, Bauters F, Fegueux N, Fey M, Sanz M, Löwenberg B, Maloisel F, Auzanneau G, Sadoun A, Gardin C, Bastion Y, Jacky E, Dombret H, Chastang C, Degos L, The European APL 91 group. Effect of all trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 32419.
  • 21
    Frankel SR, Eardley A, Heller G, Berman E, Miller WH, Dmitrovsky E, Warrell R Jr All-trans retinoic acid for acute promyelocytic leukemia. Ann Int Med 1994; 120: 27886.
  • 22
    Kanamaru A, Takemoto Y, Tanimoto M, Murakami H, Asou N, Kobayashi T, Kuriyama K, Ohmoto E, Sakamaki H, Tsubaki K, Kiraoka A, Yamada O, Oh H, Saito K, Matsuda S, Minato K, Ueda T, Ohno R, The Japan Adult Leukemia Study Group. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia. Blood 1995; 85: 12026.
  • 23
    Avvisati G, Lo Coco F, Deaver D, Falda M, Ferrara F, Lazzarino M, Russo D, Petti MC, Mandelli F. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia. Blood 1996; 88: 13908.
  • 24
    Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997; 90: 1014.
  • 25
    Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Bloomfield CD, Head DR, Weinstein HJ, Woods WG, Rowe JM, Wiernik PH. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997; 337: 10218.
  • 26
    Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Woods WG, Ogden A, Weinstein H, Shepherd L, Willman C, Bloomfield CD, Rowe JM, Wiernik PH. All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup Protocol. Blood 2002; 100: 4298302.
  • 27
    Asou N, Adachi K, Tamura J, Kanamaru A, Kageyama S, Hiraoka A, Omoto E, Akiyama H, Tsubaki K, Saito K, Kurayama K, Oh H, Kitano K, Miyawaki S, Takeyama K, Yamada O, Nishikawa K, Takahashi M, Matsuda S, Ohtake S, Suzushima H, Emi N, Ohno R. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 1998; 16: 7885.
  • 28
    Watanabe R, Murata M, Takayama N, Tokuhira M, Kizaki M, Okamoto S, Kawai Y, Watanabe K, Murakomi H, Kikuchi M, Nakamura S, Ikeda Y. Long-term follow-up of hematostatic molecular markers during remission induction therapy with all-trans retinoic acid for acute promyelocytic leukemia. Thromb Haemost 1997; 77: 641.
  • 29
    Kawai Y, Watanabe K, Kizaki M, Murata M, Kamata T, Uchida H, Moriki T, Yokoyama K, Tokuhira M, Nakajima H, Handa M, Ikeda Y. Rapid improvement in the coagulopathy by all-trans retinoic acid in acute promyelocytic leukemia. Am J Hematol 1994; 46: 1848.
  • 30
    Dombret H, Scrobohaci ML, Daniel MT, Miclea JM, Castaigne S, Chomienne C, Fenaux P, Degos L. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995; 9: 1924.
  • 31
    Falanga A, Lacoviello L, Evangelista V, Belotti D, Consonni R, D'Oranzio A, Robba L, Donati MB, Barbui T. Loss of blast cell procoagulant activity and improvement of hemostatic variables in patients with acute promyelocytic leukemia administered all-trans retinoic acid. Blood 1995; 86: 107281.
  • 32
    De Stefano V, Teofili L, Sica S, Mastrangelo S, Di Mario A, Rutella S, Salutari P, Rumi C, D'Onofrio G, Leone G. Effect of all-trans retinoic acid on procoagulant and fibrinolytic activities of cultured blast cells from patients with acute promyelocytic leukemia. Blood 1995; 86: 353541.
  • 33
    Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukemia. Br J Haematol 1976; 33: 4518.
  • 34
    Escudier SM, Kantarjian HM, Estey EH. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid. Leuk Lymph 1996; 20: 4359.
  • 35
    Kwaan HC, Wang J, Boggio LN. Abnormalities in hemostasis in acute promyelocytic leukemia. Hematol Oncol 2001; 19: 110.
  • 36
    Bennett B, Booth NA, Croll A, Dawson AA. The bleeding disorder in acute promyelocytic leukemia: fibrinolysis due to u-PA rather than defibrination. Br J Haematol 1989; 71: 5117.
  • 37
    Stephens R, Alitalo R, Tapiovaara H, Vaheri A. Production of an active urokinase by leukemia cells: a novel distinction from cell lines of solid tumors. Leuk Res 1988; 12: 41922.
  • 38
    Garcia Frade LJ, Sureda A, Torrado MC, Garcia Avello A. High plasma urokinase-type plasminogen activator levels are present in patients with acute nonlymphocytic leukemia. Acta Haematol 1992; 88: 710.
  • 39
    Tapiovaara H, Matikainen S, Hurme M, Vaheri A. Induction of differentiating therapy of promyelocytic NB4 cells by retinoic acid is associated with a rapid increase in urokinase activity subsequently downregulated by production of inhibitors. Blood 1994; 83: 188391.
  • 40
    Sakata Y, Murakami T, Noro A, Mori K, Matsuda M. The specific activity of plasminogen activator inhibitor-1 in disseminated intravascular coagulation with acute promyelocytic leukemia. Blood 1991; 77: 194957.
  • 41
    Brower NS, Harpel PC. Proteolytic cleavage and inactivation of alpha-2 plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem 1982; 257: 984954.
  • 42
    Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KW. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1999; 340: 9941004.
  • 43
    Saito T, Koyama T, Nagata K, Kamiyama R, Hirosawa S. Anticoagulant effects of retinoic acids on leukemic cells. Blood 1996; 87: 65765.
  • 44
    Wang J, Weiss I, Svoboda K, Kwaan HC. Thrombogenic role of cells undergoing apoptosis. Br J Haematol 2001; 115: 38291.
  • 45
    Falanga A, Consonni R, Marchetti M, Locatelli G, Garattini E, Gambacorti Passerini C, Gordon SG, Barbui T. Cancer procoagulant and tissue factor are differentially modulated by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 1998; 92: 14351.
  • 46
    Hair GA, Padula S, Zeff R, Schmeizel M, Contrino J, Kreutzer DL, De Moerloose P, Boyd AW, Stanley I, Burgess AW, Rickles FR. Tissue factor expression in human leukemic cells. Leukemia Res 1996; 1: 111.
  • 47
    Zhao W, Wang H, Wang X, Wu F, Guo W, Qu B, Shen Z, Wang Z. Effects of all-trans-retinoic acid and arsenic trioxide on the hemostatic disturbance associated with acute promyelocytic leukemia. Thromb Res 2001; 102: 197204.
  • 48
    Shoji M, Abe K, Nawroth PP, Rickles FR. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trend Cardiovasc Med 1997; 7: 529.
  • 49
    Oeth P, Yao J, Fan S-T, Mackman N. Retinoic acid selectively inhibits lipopolysaccharide induction of tissue factor gene expression in human monocytes. Blood 1998; 91: 285765.
  • 50
    Zhu J, Guo WM, Yao YY, Zhao WL, Pan L, Cai X, Ju B, Sun GL, Wang HL, Chen SJ, Chen GQ, Caen J, Chen Z, Wang ZY. Tissue factors on acute promyelocytic leukemia and endothelial cells are differentially regulated by retinoic acid, arsenic trioxide and chemotherapeutic agents. Leukemia 1999; 13: 106270.
  • 51
    Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH Jr. The PML/RARα oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 1996; 88: 282632.
  • 52
    Brand K, Flwler BJ, Edgington TS, Mackman N. Tissue factor mRNA in THP-1 monocytic cells is regulated at both transcriptional and posttranscriptional levels in response to lipopolysaccharide. Mol Cell Biol 1991; 11: 47328.
  • 53
    Cheng G-X, Zhu X-H, Men X-Q, Wang L, Huang QH, Jin XL, Xiong S-M, Guo W-M, Chen J-Q, Xu S-F, So E, Chan L-C, Waxman S, Zelent A, Chen G-Q, Dong S, Liu J-X, Chen S-J. Distinct leukemia phenotypes in transgenic mice and different corepressor interactions generated by promyelocytic leukemia variant fusion genes PLZF-RARα and NPM-RARα. Proc Nat Acad Sci USA 1999; 96: 631823.
  • 54
    Russell NH. Autocrine growth factors and leukemic haempoiesis. Blood Rev 1992; 6: 14956.
  • 55
    Dubois C, Schlageter MH, De Gentile A, Balitrand N, Toubert ME, Krawice I, Fenaux P, Castaigne S, Najean Y, Degos L, Chomienne C. Modulation of IL-8, IL-1β and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. Leukemia 1994; 8: 17507.
  • 56
    Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP Jr. The ‘retinoic acid syndrome’ in acute promyelocytic leukemia. Ann Intern Med 1992; 117: 2926.
  • 57
    De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, De La Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group Blood 1998; 92: 27128.
  • 58
    Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A, Shepherd L, Rowe JM, Francois C, Larson RS, Wiernik PH. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 2000; 95: 905.